Loading page
Loading page
Loading substance route
Onset and duration are dose-dependent; low doses typically produce effects for 8-12 hours, while higher doses may extend duration to 24-72 hours.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Chronic use of buprenorphine can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings may occur if a person suddenly stops their usage.
Chronic administration produces physical dependence of the opioid type, characterized by withdrawal signs and symptoms upon abrupt discontinuation or rapid taper. The withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset. Symptoms include body aches, diarrhea, nausea, anxiety, tremors, tachycardia, insomnia, sweating, and weakness.
Buprenorphine has a lower incidence of fatal overdose relative to full opioid agonists due to a ceiling effect on respiratory depression, typically reached between 16mg and 32mg. However, deaths of opioid-naive individuals have been reported at doses as low as 2mg sublingual. Overdoses are difficult to treat with the opioid antagonist naloxone due to buprenorphine's high receptor binding affinity, potentially requiring respiratory stimulants. The risk of fatal overdose increases substantially when combined with benzodiazepines, alcohol, or other CNS depressants.
Hepatotoxicity ranging from transient asymptomatic elevations in liver enzymes to rare cases of hepatic failure, hepatic necrosis, and hepatic encephalopathy has been observed; many cases involved pre-existing liver disease, viral hepatitis co-infection, concurrent hepatotoxic drugs, or ongoing injection drug use.
Chronic opioid use may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility; adrenal insufficiency has also been reported, more often following greater than one month of use.
Central sleep apnea has been reported as a side effect of long-term buprenorphine use, though it may resolve with dose reduction.
QT prolongation and orthostatic hypotension may occur with buprenorphine use.
Among those with a history of seizures, a risk exists of further seizures. No notable seizure risk is documented in individuals without pre-existing seizure disorders.
Buprenorphine emerged from a decade-long research program at Reckitt & Colman (now Reckitt Benckiser) in Hull, England, where scientists sought to synthesize opioid compounds that retained therapeutic analgesic properties while minimizing the problematic effects of physical dependence and abuse…
Legal for medical use under the Arzneimittelgesetz (AMG). Possession or sale without a valid prescription is prohibited under the Suchtmittelgesetz (SMG). Available as Temgesic for pain and Subutex for opioid addiction treatment.
Available by prescription only as Subutex in 2 mg tablet form for opioid addiction treatment. While pharmacies stock the medication, prescriptions may only be written by approved addiction treatment physicians.
Prescription by general practitioners and dispensation by pharmacies has been permitted since the mid-1990s as part of harm reduction efforts addressing HIV transmission and overdose risk among people who use drugs.
Controlled under List II of the Opium Law with special rules governing prescription and dispensation. Available by prescription as Temgesic in 0.2 mg sublingual tablets for severe pain, and by injection in hospital settings.
Controlled as a Schedule II substance under Russian narcotics legislation. Subject to strict prescription and distribution controls.
Listed as a controlled substance under Verzeichnis A of the Swiss narcotics regulations. Medicinal use is permitted under appropriate medical supervision.
Controlled under the Misuse of Drugs Act 1971. Requires a prescription or license for lawful possession. A Home Office license is required for export. Commonly prescribed for treatment of heroin, methadone, or other severe opioid dependence.
Controlled under the Controlled Drugs and Substances Act. Only available with a valid prescription from a licensed practitioner.
Available by prescription as Temgesic for pain management, which can be obtained from pharmacies. Subutex for opioid addiction treatment must be dispensed through approved addiction treatment physicians rather than regular pharmacies.
Controlled under the Betäubungsmittelgesetz (Narcotics Act, Schedule III) since September 1, 1984. Requires a special narcotic prescription form (Betäubungsmittelrezept). Available as Temgesic for pain management and Subutex for opioid addiction treatment.
Classified as a Class A controlled substance under Norwegian drug legislation. Available as Temgesic (0.3 mg) for pain relief and Subutex and Suboxone (8 mg formulations) for opioid addiction treatment.
Classified as a Class IV controlled substance. Available as Temgesic (0.2 and 0.4 mg sublingual tablets, 0.3 mg/ml injection) and Subutex (0.4, 2, and 8 mg sublingual tablets). While any physician may technically prescribe Subutex, official guidance recommends that only practitioners at drug treatment centers prescribe it for addiction.
Available only as part of official addiction treatment programs. Requires a prescription from a physician working at an addiction clinic, must be purchased from a major hospital, and the patient must demonstrate absence of other opioid use via urine screening. Available as buprenorphine/naloxone combination preparations in 2 mg/0.5 mg and 8 mg/2 mg formulations.
Rescheduled by the DEA from Schedule V to Schedule III in 2002, just prior to FDA approval for opioid use disorder treatment. The Drug Addiction Treatment Act of 2000 established a waiver system allowing qualified physicians to prescribe buprenorphine for addiction treatment outside specialized clinics. Prescriber patient limits were progressively increased from 10 to 30, then 100, and eventually 275 patients. As of January 2021, the waiver requirement was eliminated for prescribing to up to 30 patients concurrently.
14 sources cited